We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: 抗病毒疗法
MedXY News
EnglishTag

抗病毒疗法

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood Transplant
Infectious Diseasescord blood transplantationsurvival outcomes

Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood Transplant

By MedXY|Apr 24, 2026

A real-world study reveals FCN/GCV combination therapy enhances 1-year survival in HHV-6B encephalitis post-CBT, particularly after neutrophil engraftment, compared to monotherapy. Findings underscore the need for tailored antiviral strateg

Potent Inhibition of Hepatitis E Virus Replication by Bemnifosbuvir: Preclinical Evidence and Clinical Prospects
Clinical UpdatesViêm gan EViêm gan mãn tính

Potent Inhibition of Hepatitis E Virus Replication by Bemnifosbuvir: Preclinical Evidence and Clinical Prospects

By MedXY|Mar 8, 2026

Preclinical studies demonstrate that the nucleotide analogue bemnifosbuvir effectively suppresses Hepatitis E virus (HEV) replication, showing synergistic potential with ribavirin and a high genetic barrier to resistance.

Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection
GastroenterologyALG-000184Capsid Assembly Modulator

Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection

By MedXY|Mar 2, 2026

This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potenti

Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial
Clinical UpdatesALG-000184Capsid Assembly Modulator

Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial

By MedXY|Mar 2, 2026

This review synthesizes the Phase 1 trial findings of ALG-000184, a novel capsid assembly modulator, demonstrating significant multi-log reductions in HBV DNA and RNA with a favorable safety profile in chronic HBV patients.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story